Evaluation and management of special subgroups after primary percutaneous coronary intervention

American Heart Journal

Volumn 160, Issue 6 SUPPL., 2010, Pages

  De Luca, Leonardo ^a   Tomai, Fabrizio ^a   Verdoia, Monica ^b   De Luca, Giuseppe ^b  

^a EUROPEAN HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; CALCIUM CARBONATE; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE SYNTHASE; ORAL ANTIDIABETIC AGENT; PRASUGREL; TIROFIBAN;

AORTA BALLOON; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CAROTID ARTERY DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG WITHDRAWAL; ELDERLY CARE; HEART ASSIST DEVICE; HEART FAILURE; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; HYPERTENSION; INTRACARDIAC THROMBOSIS; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE DISEASE; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; DIABETES COMPLICATIONS; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HEART-ASSIST DEVICES; HUMANS; KIDNEY DISEASES; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; SHOCK, CARDIOGENIC;

EID: 78650149571     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.10.012     Document Type: Article

References (40)

1. Holmes D.R. Jr, White H.D., and Pieper K.S. Effect of age on outcome with primary angioplasty versus thrombolysis J Am Coll Cardiol 33 1999 412 419
2. De Luca G., van 't Hof A.W., and Ottervanger J.P. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty Eur Heart J 26 2005 662 666
3. De Luca G., Suryapranata H., and Ottervanger J.P. Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction Int J Cardiol 119 2007 306 309
4. Alexander K.P., Chen A.Y., and Roe M.T. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 294 2005 3108 3116
5. Mak K.H., Effron M.B., and Moliterno D.J. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients Drugs Aging 16 2000 179 187
6. Stone G.W., Witzenbichler B., and Guagliumi G. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
7. Wiviott S.D., Braunwald E., and McCabe C.H. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
8. Pan M., Suárez de Lezo J., and Medina A. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation Am J Cardiol 80 1997 1336 1338
9. De Luca G., Suryapranata H., and Timmer J. Impact of routine stenting on clinical outcome in diabetic patients undergoing primary angioplasty for ST-segment elevation myocardial infarction Diabetes Care 29 2006 920 923
10. De Luca L., De Persio G., and Minati M. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting Am Heart J 149 2005 1135
11. Timmer J.R., Svilaas T., and Ottervanger J.P. Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II J Am Coll Cardiol 47 2006 1730 1731
12. Timmer J.R., van der Horst I.C., and De Luca G. Zwolle Myocardial Infarction Study Group. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus Am J Cardiol 95 2005 1375 1377
13. De Luca G., Gibson M.C., and Bellandi F. Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation J Thromb Thrombolysis 28 2009 288 298
14. Mehta S.R., Tanguay J.F., and Eikelboom J.W. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
15. Wiviott S.D., Braunwald E., and Angiolillo D.J. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
16. Prasad A., Stone G.W., and Stuckey T.D. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction J Am Coll Cardiol 45 2005 508 514
17. Iijima R., Byrne R.A., and Dibra A. Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials Rev Esp Cardiol 62 2009 354 364
18. De Luca G., Sauro R., and Varricchio A. Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES J Thromb Thrombolysis 30 2010 133 141
19. Tomai F., Petrolini A., and De Luca L. Rationale and design of the Randomized comparison of XiEnce V and Multilink VisioN coronary stents in the sAme muLtivessel patient with chronic kidney disease (RENAL-DES) study J Cardiovasc Med 11 2010 310 317
20. Sadeghi H.M., Stone G.W., and Grines C.L. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction Circulation 108 2003 2769 2775
21. Marenzi G., Moltrasio M., and Assanelli E. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty Am Heart J 153 2007 755 762
22. Yamaguchi J., Kasanuki H., and Ishii Y. Serum creatinine on admission predicts long-term mortality in acute myocardial infarction patients undergoing successful primary angioplasty: data from the Heart Institute of Japan Acute Myocardial Infarction (HIJAMI) Registry Circ J 71 2007 1354 1359
23. Zhao L., Wang L., and Zhang Y. Elevated admission serum creatinine predicts poor myocardial blood flow and more one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention J Invasive Cardiol 21 2009 493 496
24. Melloni C., Peterson E.D., and Chen A.Y. Cockcroft-Gault versus Modification of Diet in Renal Disease. Importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes J Am Coll Cardiol 51 2008 991 996
25. Mehran R., Aymong E.D., and Nikolsky E. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation J Am Coll Cardiol 44 2004 1393 1399
26. Eikelboom J.W., Mehta S.R., and Anand S.S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
27. Park H., Kim W., and Park C.S. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure Am J Cardiol 104 2009 1292 1295
28. Small D.S., Wrishko R.E., and Ernest C.S. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease J Clin Pharm Ther 34 2009 585 594
29. Reynolds H.R., and Hochman J.S. Cardiogenic shock. Current concepts and improving outcomes Circulation 117 2008 686 697
30. Antman E.M., Anbe D.T., and Armstrong P.W. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation 110 2004 588 636
31. Reynolds H.R., Anand S.K., and Fox J.M. Restrictive physiology in cardiogenic shock: observations from echocardiography Am Heart J 151 2006 890.e9 890.e15
32. Cheng J.M., den Uil C.A., and Hoeks S.E. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials Eur Heart J 17 2009 2102 2108
33. Windecker S. Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock Curr Opin Crit Care 13 2007 521 527
34. Schreiber W., Herkner H., and Koreny M. Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support Resuscitation 55 2002 269 276
35. Valente S., Lazzeri C., and Vecchio S. Predictors of in-hospital mortality after percutaneous coronary intervention for cardiogenic shock Int J Cardiol 114 2007 176 182
36. Müllner M., Urbanek B., and Havel C. Vasopressors for shock Cochrane Database Syst Rev 2004 CD003709
37. De Luca L., Colucci W.S., and Nieminen M.S. Evidence-based use of levosimendan in different clinical settings Eur Heart J 16 2006 1908 1920
38. Fuhrmann J.T., Schmeisser A., and Schulze M.R. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction Crit Care Med 36 2008 2257 2266
39. Dzavík V., Cotter G., Reynolds H.R. for the SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study Eur Heart J 28 2007 1109 1116
40. The TRIUMPH Investigators Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock. The TRIUMPH randomized controlled trial JAMA 297 2007 1657 1666